Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Some family I DNA ligases can use dATP as nucleotide
2021-06-04

Some family I DNA ligases can use dATP as nucleotide cofactor. For instance, human Alogliptin mg I uses dATP with a catalytic efficiency that is only 36-fold lower in comparison to ATP [9]. EhDNAlig is unable to use dATP as a nucleotide cofactor, indicating a more constrained active site in comparis
-
br Experimental section br Author
2021-06-04

Experimental section Author contributions Acknowledgements Introduction Many TNKS 49 in cells are sequential enzymatic reactions where the product of one enzyme serves as the substrate of a second enzyme (1, 2). Experimental evidence suggests that some of these consecutive enzyme-catalyz
-
We note that there are slight qualitative
2021-06-03

We note that there are slight qualitative differences among the similar time-optimal protocols. We attribute this to the challenging nature of our PDE and ODE state constrained optimization problem. While our optimization algorithm was able to converge to local optima in each case, it is likely that
-
During ischemia the impact of CK on
2021-06-03

During ischemia, the impact of CK2 on mitochondria varies in different organs/tissues. For example, CK2α upregulation during ischemia leads to disrupted mitochondrial homeostasis and mediates cardiomyocyte ischemic injury [31]. Specifically, ischemia/reperfusion (I/R) progressively increases CK2α to
-
An additional difference in ACC between
2021-06-03

An additional difference in ACC-1 between H. contortus and C. elegans is the results from the oocyte expression experiments. Here we found that unlike Cel-ACC-1 that was reported to form a functional homomeric channel (Putrenko et al., 2005), Hco-ACC-1 does not. However, we have observed that in gen
-
Protein ubiquitination occurs at the
2021-06-03

Protein ubiquitination occurs at the lysine residues, and is mediated by the sequential reactions of ubiquitin-activating enzyme (E1), conjugating enzyme (E2), and ligase (E3). The first step in this process comprises the ATP-dependent activation of ubiquitin by E1 to form a ubiquitin–E1 conjugate.
-
Introduction Glucose is the major
2021-06-03

Introduction Glucose is the major carbon source in most organisms. Cancer Eptifibatide in particular require a steady source of energy to maintain growth and proliferation, and preferentially use glycolysis for their energy supply even under aerobic conditions. Glucose uptake in mammals is mainly
-
br Introduction Epidermal growth factor receptor EGFR activa
2021-06-03

Introduction Epidermal growth factor receptor (EGFR)-activating-mutant non-small cell lung cancer (NSCLC) often initially responds well to EGFR tyrosine kinase inhibitors (TKIs) (Haber et al., 2011); however, the disease almost always recurs about 10–13 months of therapy. Analysis of clinical spe
-
br Results and discussion br Conclusion We
2021-06-03

Results and discussion Conclusion We have constructed a series of potent and greatly selective DPP-4 inhibitors with pyrazolo[1,5-a]pyrimidin-7(4H)-one core surrogates. The modification of the core led us to b2 which has IC50 of 80 nM and > 1000 fold selectivity over DPP-8 and DPP-9. We utiliz
-
HPK 56 australia The Lysine mutant is located in the tail re
2021-06-03

The Lysine429 mutant is located in the tail region of 5-HT2A, which is predicted to be unstructured. This region has been shown to interact, in vitro, with PSD95 and leads to differences in signaling (Xia et al., 2003). The ASK motif, a component of the tail region, is also important for regulation
-
Homologous recombination HR has important
2021-06-03

Homologous recombination (HR) has important roles in the repair of stalled or collapsed DNA replication forks, as well as of DNA double-strand breaks. Among the factors required for HR in human GSK J4 free base are RAD51, BRCA1, and BRCA2 (Davies et al., 2001, Sung and Klein, 2006, Xia et al., 2001
-
Some pyrimidine analogs are substrate based inhibitors that
2021-06-02

Some pyrimidine analogs are substrate-based inhibitors that bind to the dihydroorotate binding site, but most reported inhibitors of DHODH bind to the site occupied by the ubiquinone co-factor., , , , , , , , , , , , , , , , , X-ray crystallographic studies of inhibitor complexes with DHODH and DHO
-
Risedronate mg br Experimental All starting materials and
2021-06-02

Experimental All starting materials and reagents were purchased from Sigma-Aldrich, Merck and Loba Chemie. Thin layer chromatography (TLC) was performed on silica gel G60 F254 (Merck) plates and eluted with the mobile phase n-hexane: ethyl acetate (70:30%v/v). Melting points were recorded on auto
-
In order to assess quantitatively the contribution of
2021-06-02

In order to assess quantitatively the contribution of the ung, dug and dut Nifedipine to uracil-DNA accumulation in E. coli, we have developed a novel method for measuring uracil residues in DNA that is based on the approach of Kow and co-workers [33] for measuring AP-sites in DNA. The method, whic
-
The field of synthetic cytokine biology continues to grow
2021-06-02

The field of synthetic cytokine biology continues to grow through molecular, physiological and pathophysiological insights, as well as via new methodical advances. The approval of chimeric antigen receptor (CAR) T cell immunotherapy by the US Food and Drug administration (FDA) in August 2017 for rel
15924 records 631/1062 page Previous Next First page 上5页 631632633634635 下5页 Last page